Share
2,563 Posts.
lightbulb Created with Sketch. 75
clock Created with Sketch.
13/04/16
18:23
Share
Originally posted by Dr x
↑
Hello all. Intern dr here. From what I have learned, it would be unlikely that RESAPP would be able to distinguish from different strains of influenza. What you are referring to is switches in genetic codes in haemagglutinin and neuraminidase receptors (things on the surface of the virus itself) which simply render the body's immune system incapable of recognising the virus. Mode of transmission and symptoms are identical, thus cough would remain the same.
That being said, I do have a little to offer on the potential ability of Resapp in the area of pneumonia/bronchitis/bronchiolitis/ other diseases of the respiratory tract. For pneumonia, gold standard test is CXR (Chest X-Ray) currently with a sensitivity of about 80%. Now you might be wondering what sensitivity and specifity mean in the tables of data that RAP has presented. Simply put, sensitivity is of all those who are marked as not having the disease by the test, the amount that actually do not have the disease (true negative/true negative + false positive) whereas specifity is if the test comes back positive, the likelihood one actually has the disease (true positive/true positive+false negative). Rap's diagnostic means has essentially blown away cxr with a much high sensitivity (more important stat) for pneumonia. Plus with its ability to differentiate between bacterial/viral, doctor could star ptx on broad spectrum antibiotics before a culture comes back with the offending pathogen.
Now I know all this has been said before but was just offering my medical insight into the matter. Objectively, Rap is a stock bound for success. If the statistics do not lie then this is truly a once in a lifetime opportunity. I am excited to see this skyrocket.
I just have a couple of questions for the forum, as I am a newbie trader (been doing Med, what do you expect). What is your opinion of what the reaction will be once the revenue is released in June/July? Would DT/ST move onto other due to lack of short term profit?. I speak not with any knowledge on this matter but rather what I have heard on the grapevine.
Thanks for your responses. Excited for the future of this company as it will inevitably replace current respiratory diagnoses methods!!
X
Expand
Hi x
Nice post.
There are many ways to value a company and different methods will wax and wane in popularity. The share price of a company tends to reflect anticipated value and how far investors look into the future will vary.
I will expect rap to be close to 75c per share after full adult results from America are released, if results are good.
I am always wrong on this stuff, I have learned that if I am right about a company, the share price will prove me right eventually.
If hold rap for 12 months, I pay less capital gains tax if I make a profit. Patience on the side of being right is the best thing